Shots:
Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets
As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development…
